Basal STAT3 activities are negatively correlated with tumor size in papillary thyroid carcinomas

Journal of Endocrinological Investigation

Volumn 35, Issue 4, 2012, Pages 413-418

  Kim, W G ^a   Choi, H J ^b   Kim, W B ^a   Kim, E Y ^a   Yim, J H ^a   Kim, T Y ^a   Gong, G ^a   Kim, S Y ^a   Chung, N ^b   Shong, Y K ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea University   (South Korea)

Author keywords

Mutation; Papillary carcinoma; Prognosis; Proto oncogene protein B raf; STAT3 transcription factor; Thyroid neoplasm

Indexed keywords

STAT3 PROTEIN;

ADULT; ARTICLE; B RAF GENE; CANCER PROGNOSIS; CLINICAL ARTICLE; DNA BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; SIGNAL TRANSDUCTION; THYROID CARCINOMA; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; CARCINOMA; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; STAT3 TRANSCRIPTION FACTOR; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84863961382     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7907     Document Type: Article

References (27)

1. Leaman DW, Leung S, Li X, Stark GR. Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J 1996, 10: 1578-88. (Pubitemid 27043774)
2. Calò V, Migliavacca M, Bazan V, et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 2003, 197: 157-68. (Pubitemid 37485244)
3. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264: 1415-21. (Pubitemid 24217131)
4. Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995, 64: 621-51.
5. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995, 82: 241-50.
6. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000, 19: 2474-88. (Pubitemid 30339203)
7. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002, 109: 1139-42. (Pubitemid 34496590)
8. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999, 98: 295-303. (Pubitemid 29380565)
9. Zhou P, Qian L, Bieszczad CK, et al. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 1998, 92: 3226-39. (Pubitemid 28492330)
10. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10: 105-15. (Pubitemid 29077388)
11. Niu G, Wright KL, Ma Y, et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 2005, 25: 7432-40. (Pubitemid 41170107)
12. Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, Jove R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 2000, 19: 5419-27. (Pubitemid 32000908)
13. Bowman T, Broome MA, Sinibaldi D, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A 2001, 98: 7319-24. (Pubitemid 32567946)
14. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21: 2000-8. (Pubitemid 34270888)
15. Xie TX, Wei D, Liu M, et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004, 23: 3550-60. (Pubitemid 38658421)
16. Xu Q, Briggs J, Park S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005, 24: 5552-60. (Pubitemid 43119350)
17. Katoh R, Bray CE, Suzuki K, et al. Growth activity in hyperplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1. Hum Pathol 1995, 26: 139-46.
18. Soares P, Sobrinho-Simões M. Correspondence re: G. Tallini et al., RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotype. Clin. Cancer Res., 4:287-294, 1998. Clin Cancer Res 1999, 5: 3724-5.
19. Yamamoto Y, Maeda T, Izumi K, Otsuka H. Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases. Cancer 1990, 65: 1173-9. (Pubitemid 20072054)
20. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001, 86: 1447-63. (Pubitemid 32374886)
21. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005, 12: 245-62. (Pubitemid 40896444)
22. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005, 65: 4238-45. (Pubitemid 40775662)
23. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983, 11: 1475-89.
24. Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005, 63: 588-93. (Pubitemid 41626756)
25. Benekli M, Xia Z, Donohue KA, et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 2002, 99: 252-7.
26. Corvinus FM, Orth C, Moriggl R, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005, 7: 545-55. (Pubitemid 40967755)
27. Vultur A, Cao J, Arulanandam R, et al. Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene 2004, 23: 2600-16. (Pubitemid 38586314)